Drug Trial Radar · NCT00869635
S-1 and Photodynamic Therapy in Cholangiocarcinoma
Last checked: Nov 19, 2026Latest source record: Feb 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Feb 2009
Primary completion
Jul 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Asan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In patients with unresectable perihilar cholangiocarcinoma, photodynamic therapy with biliary stent has been known for palliation of jaundice and improving survival. But most of therapeutic effects were expected to delay bile duct obstruction rather than to decrease the tumor. Recently orally available chemotherapeutic agent, S-1 was reported as effective in patients with bile duct adenocarcinoma. The investigators' aims of study evaluate the combined effect of photodynamic therapy and S-1.
Conditions
- Cholangiocarcinoma
Interventions
S-1 ChemotherapyDrug
S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, \<1.25m2: 80mg/day, 1.25\~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
Photodynamic therapyProcedure
PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
Systemic chemotherapy except S-1Procedure
Variable systemic chemotherapy except S-1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare overall survival time in patients with unresectable perihilar cholangiocarcinoma treated with photodynamic therapy combined with or without S-1Time frame: 12 months after study start
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.